Ribo Life Science is a Chinese pharmaceutical company. The company was reported to have raised 470 million yuan (approximately $66 million) in a Series C2 financing. The financing figure and round type were published in a China Digest item that also covered other regional deals. The article did not disclose participating investors or the stated use of proceeds. No operating metrics, past rounds, founding year, or detailed product information were provided in the report. The only financial detail provided in the article is the size and series of this latest round.

Total raised

$66M

Funding rounds

1

Latest round

Series C

Latest activity

Apr 2020